Topic Archives: MEI Pharma (MEIP)

MEI Pharma ($MEIP) is a NASDAQ-listed $133M biotech based in San Diego that was spun out by prior owner Australian biotech Novogen ($NVGN), a firm now facing NASDAQ delisting for failing to meet requirements, in 2012. Though I can certainly understand the reluctance of rational biotech investors to avoid any firm even vaguely associated with […]


No comments.

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info